Assessing the Clinical Improvement in Patients with COVID-19 using Lopinavir-Ritonavir: A Systematic Review | Zendy

Rania Magadmi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Assessing the Clinical Improvement in Patients with COVID-19 using Lopinavir-Ritonavir: A Systematic Review

Author(s) -

Rania Magadmi

Publication year - 2021

Publication title -

journal of pharmaceutical research international

Language(s) - English

Resource type - Journals

ISSN - 2456-9119

DOI - 10.9734/jpri/2021/v33i44a32637

Subject(s) - lopinavir , ritonavir , lopinavir/ritonavir , covid-19 , medicine , pandemic , intensive care medicine , pharmacology , virology , disease , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , infectious disease (medical specialty)

Aims: Globally the focus is towards finding an effective treatment for COVID-19 patients in order to suppress the spread of this pandemic disease. An antiviral combination of lopinavir-ritonavir is considered to be effective in treating COVID-19 patients. Therefore, the present study aims to assess the clinical improvements of lopinavir-ritonavir in COVID-19 patients. Study Design: a systematic review study was conducted and articles published since December 2019 were included. The statistical analysis of quantitative data was performed using Review Manager (RevMan) to generate forest plots. Results: The study showed that there was no significant difference in COVID-19 patients treated with lopinavir-ritonavir or in combination with anti-viral therapy or other conventional methods. Conclusion: the use of lopinavir-ritonavir resulted in greater adverse consequences among COVID-19 patients. It further recommends conducting meta-analysis studies with a greater number of studies to highlight the clinical improvement associated with the use of Lopinavir-ritonavir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research